Noah Goodman

Noah is Vice President of Business Development at Chroma Medicine. He joined Chroma from Cadent Therapeutics, where, as Executive Director and Head of Business Development, he led Cadent’s acquisition by Novartis for up to $770M. Prior to Cadent, Noah was Head of Business Development at Seres Therapeutics, where he was responsible for leading collaborations and licensing transactions across several therapeutic areas including the company’s collaboration with AstraZeneca. Noah also worked in business development at Spark Therapeutics and as a management consultant at Easton Associates (now part of Navigant Consulting), a boutique life sciences consultancy, where he advised clients on corporate strategy and business development. Noah holds a B.S. in neuroscience from the University of Michigan and an M.B.A. from the Wharton School of the University of Pennsylvania.